In this online, self-learning activity:
Renal cell carcinoma (RCC) is a cancer that develops in the nephrons. It is responsible for most cancers of the kidney and renal pelvis, which occur in close to 82,000 people and account for close to 15,000 deaths in the U.S. annually. The five-year survival rate is 93% for patients with early stages of the disease. However, in patients with advanced or metastatic disease, the five-year survival is 15%, representing an area of ongoing clinical need.
HCPs including: medical oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with RCC.
Commercial Support Disclosure: This program is supported by an educational grant from Aveo Pharmaceuticals and Merck.
This activity is free of charge.
Release Date: May 21, 2024 -- Expiration Date: May 21, 2025
Faculty: Adam Singer, MD, PhD
Faculty introduction, disclosures |
|
Introductory content and review of advanced RCC
|
|
Treatment considerations for advanced RCC, including guideline-based approaches and clinical trial evidence
|
|
Summary, conclusions, and best practice recap |
|
By the end of the session the participant will be able to:
ACCME Activity #202786621
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor of Medicine, David Geffen School of Medicine, UCLA, has received financial compensation from AVEO Oncology and Adaptyx Bio for consulting.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Aveo Pharmaceuticals and Merck.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Advanced systemic mastocytosis: from recognition to treatment
Melanoma - updates from the European Society for Medical Oncology (ESMO) 2023